Tumour expression of bladder cancer-associated urinary proteins

BJU International

Volumn 112, Issue 3, 2013, Pages 407-415

  Lindén, Mårten ^a   Segersten, Ulrika ^a   Runeson, Marcus ^b   Wester, Kenneth ^b   Busch, Christer ^b   Pettersson, Ulf ^b   Lind, Sara Bergström ^b   Malmström, Per Uno ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

bladder cancer; immunohistochemistry; tissue microarray; urinary protein markers

Indexed keywords

ALPHA 1 ANTITRYPSIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE 2A; FIBRINOGEN; FIBRINOGEN BETA CHAIN PRECURSOR; GLYCOPROTEIN; LEUCINE RICH ALPHA2 GLYCOPROTEIN; POLYMERASE RNA I POLYPEPTIDE E; PROTEIN PRECURSOR; UNCLASSIFIED DRUG; URINARY PROTEIN MARKER;

AGED; ARTICLE; BLADDER CANCER; BLADDER MUCOSA; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; URINALYSIS; WESTERN BLOTTING;

BLADDER CANCER; IMMUNOHISTOCHEMISTRY; TISSUE MICROARRAY; URINARY PROTEIN MARKERS;

AGED; FEMALE; HUMANS; MALE; NEOPLASM PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 84879879480     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11653.x     Document Type: Article

References (28)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917
2. Linden M, Lind SB, Mayrhofer C, et al. Proteomic analysis of urinary biomarker candidates for nonmuscle invasive bladder cancer. Proteomics 2012; 12: 135-144
3. Major AS, Joyce S, Van Kaer L,. Lipid metabolism, atherogenesis and CD1-restricted antigen presentation. Trends Mol Med 2006; 12: 270-278
4. Videira PA, Calais FM, Correia M, et al. Efficacy of bacille Calmette-Guerin immunotherapy predicted by expression of antigen-presenting molecules and chemokines. Urology 2009; 74: 944-950
5. Petrache I, Fijalkowska I, Medler TR, et al. alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. Am J Pathol 2006; 169: 1155-1166
6. Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000; 96: 3302-3309
7. Sahni A, Simpson-Haidaris PJ, Sahni SK, Vaday GG, Francis CW,. Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (FGF-2). J Thromb Haemost 2008; 6: 176-183
8. Drygin D, Rice WG, Grummt I,. The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer. Annu Rev Pharmacol Toxicol 2010; 50: 131-156
9. Lynch J, Fay J, Meehan M, et al. MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-beta signalling pathway. Carcinogenesis 2012; 33: 976-985
10. Kim EJ, Lee YS, Kim YJ, et al. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer. Urology 2010; 75: 1516 e9-13
11. Koren R, Kugel V, Dekel Y, Weissman Y, Livne PM, Gal R,. Human DNA topoisomerase-IIalpha expression as a prognostic factor for transitional cell carcinoma of the urinary bladder. BJU Int 2003; 91: 489-492
12. Simon R, Atefy R, Wagner U, et al. HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer 2003; 107: 764-772
13. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-847
14. Sauter G, Algaba F, Amin M, et al. Non invasive Urothelial Neoplasias; WHO Classification of Non invasive Papillary Urothelial Tumours, 1st edn., Eble JN, Sauter G, Epstein J, Sesterhenn I, eds, Lyon: WHO, 2004
15. Segersten MU, Edlund EK, Micke P, et al. A novel strategy based on histological protein profiling in-silico for identifying potential biomarkers in urinary bladder cancer. BJU Int 2009; 104: 1780-1785
16. Busch C, Malmstrom PU, Norlen BJ, Sallstrom J, Brodin T, Lundblad A,. A grading system for the immunostaining of A, B and H blood group isoantigens in bladder carcinoma. Anticancer Res 1988; 8: 81-87
17. Chen YC, Pohl G, Wang TL, et al. Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res 2005; 65: 331-337
18. Martinez-Pineiro JA, Pertusa C, Maganto E, et al. Urinary fibrinogen degradation products (FDP) in bladder cancer. Eur Urol 1978; 4: 348-350
19. Mizutani Y, Nio Y, Fukumoto M, Yoshida O,. Enhanced antitumor effect of Bacillus Calmette-Guerin in combination with fibrinogen on urinary bladder tumor. J Urol 1994; 151: 1420-1426
20. Lynch J, Fay J, Meehan M, et al. MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-β signalling pathway. Carcinogenesis 2012; 33: 976-985
21. Sun D, Kar S, Carr BI,. Differentially expressed genes in TGF-beta 1 sensitive and resistant human hepatoma cells. Cancer Lett 1995; 89: 73-79
22. The Protein Atlas [database on the Internet]. The Protein Atlas Project 2012; Available at: http://www.proteinatlas.org Accessed September 2012
23. Hannan KM, Kennedy BK, Cavanaugh AH, et al. RNA polymerase I transcription in confluent cells: Rb downregulates rDNA transcription during confluence-induced cell cycle arrest. Oncogene 2000; 19: 3487-3497
24. Hanada K, Song CZ, Yamamoto K, et al. RNA polymerase I associated factor 53 binds to the nucleolar transcription factor UBF and functions in specific rDNA transcription. EMBO J 1996; 15: 2217-2226
25. Seither P, Zatsepina O, Hoffmann M, Grummt I,. Constitutive and strong association of PAF53 with RNA polymerase I. Chromosoma 1997; 106: 216-225
26. Farshchian M, Kivisaari A, Ala-Aho R, et al. Serpin peptidase inhibitor clade A member 1 (SerpinA1) is a novel biomarker for progression of cutaneous squamous cell carcinoma. Am J Pathol 2011; 179: 1110-1119
27. Normandin K, Peant B, Le Page C, et al. Protease inhibitor SERPINA1 expression in epithelial ovarian cancer. Clin Exp Metastasis 2010; 27: 55-69
28. Fristrup N, Ulhoi BP, Birkenkamp-Demtroder K, et al. Cathepsin e, maspin, plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am J Pathol 2012; 180: 1824-1834